Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating AZT and ddC in Advanced HIV
NCT00000719Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zalcitabine in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Long-term Safety and Tolerance at 48 weeks. Status: completed.
02
Drugs
zalcitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000719.